Pharmacologic Considerations in the Disposition of Antibodies and Antibody-Drug Conjugates in Preclinical Models and in Patients

Pharmacologic Considerations in the Disposition of Antibodies and Antibody-Drug Conjugates in Preclinical Models and in Patients

The rapid advancement in the development of therapeutic proteins, including monoclonal antibodies (mAbs) and antibody-drug conjugates (ADCs), has created a novel mechanism to selectively deliver highly potent cytotoxic agents in the treatment of cancer. These agents provide numerous benefits compare...

Full description

Bibliographic Details
Main Authors: Andrew T. Lucas, Ryan Robinson, Allison N. Schorzman, Joseph A. Piscitelli, Juan F. Razo, William C. Zamboni
Format: Article
Language:English
Published: MDPI AG 2019-01-01
Series:Antibodies
Subjects:
Antibody-drug conjugates
Pharmacology
Mononuclear phagocyte system
Pharmacokinetics
Therapeutic proteins
Online Access:http://www.mdpi.com/2073-4468/8/1/3

Internet

http://www.mdpi.com/2073-4468/8/1/3

Similar Items